SEC Comment Letter 0000000000-23-013932 to KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA)
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: Dec. 20, 2023 · CIK: 0001075880 · Accession: 0000000000-23-013932
AI Filing Summary & Sentiment
File numbers found in text: 333-276091
Letter
United States securities and exchange commission logo December 20, 2023 John Friend Chief Executive Officer Kazia Therapeutics Ltd. Three International Towers Level 24 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re:Kazia Therapeutics Ltd. Registration Statement on Form F-3 Filed December 15, 2023 File No. 333-276091 Dear John Friend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephanie Richards
Show Raw Text
United States securities and exchange commission logo
December 20, 2023
John Friend
Chief Executive Officer
Kazia Therapeutics Ltd.
Three International Towers Level 24
300 Barangaroo Avenue
Sydney, NSW, 2000, Australia
Re:Kazia Therapeutics Ltd.
Registration Statement on Form F-3
Filed December 15, 2023
File No. 333-276091
Dear John Friend:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Stephanie Richards